Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Fischer

Showing results (1311-1320 of 1,361) with videos related to

Pageof 137
Sort By:
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cancer Discovery|September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsQing Li, Baishan Jiang, Jiaye Guo, et al.
Nature Cancer|May 9, 2022
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemiaBrandon J Aubrey, Jevon A Cutler, Wallace Bourgeois, et al.
Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.
Blood|December 22, 2021
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1Wenchao Wu, Geoffrey M Nelson, Raphael Koch, et al.
Pageof 137

Showing results (1311-1320 of 1,361) with videos related to

Sort By:
Pageof 137
Cell Chemical Biology|February 11, 2026
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesisPeter Geon Kim, Christopher B Hergott, Aidan P Miller, et al.
Nature|June 5, 2020
The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin KMikołaj Słabicki, Zuzanna Kozicka, Georg Petzold, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Cancer Discovery|September 21, 2021
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsQing Li, Baishan Jiang, Jiaye Guo, et al.
Nature Cancer|May 9, 2022
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemiaBrandon J Aubrey, Jevon A Cutler, Wallace Bourgeois, et al.
Nature Communications|June 30, 2022
Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational statePeter G Miller, Murugappan Sathappa, Jamie A Moroco, et al.
Annals of Neurology|December 16, 2000
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research GroupJ S Fischer, R L Priore, L D Jacobs, et al.
Blood|December 14, 2023
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AMLWallace Bourgeois, Jevon A Cutler, Brandon J Aubrey, et al.
Blood|December 22, 2021
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1Wenchao Wu, Geoffrey M Nelson, Raphael Koch, et al.
Pageof 137